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1. Features of coagulation FVIII
Factor VIII, a cofactor for coagulation serine proteases is carried 
by von Willebrand factor (VWF) for protection from degradation (by 
activated protein C, aPC) in circulation. As VWF is the key localizer 
of hemostasis to the vascular injury site, the targeting of FVIII to the 
platelet and other relevant surfaces from blood fl ow, secures timely 
relevant engagement of coagulation activity and thrombin formation 
at the site of injury (Fig. 1). FVIII binds to the platelet membrane 
phospholipids and reaches FIX to form the tenase complex. This 
activates FX, which then binds to another cofactor of coagulation, 
that is FV, to capture prothrombin to be converted to thrombin and 
moreover, fi brinogen to fi brin.
The concentration of FVIII is more than 100-fold lower (0.0003 μM) 
than any other coagulation factor, which causes specifi c implications 
in the quantitative diff erences in FVIII levels. Elevated FVIII levels, i.e. 
above 190 IU/dL, carry a signifi cant thrombosis risk and refl ect also 
endothelial cell activation under various conditions, and vice versa 
lowered FVIII levels, below 30 IU/dL cause signifi cant impairment of 
hemostasis.
2. Hemophilia A is either inherited or acquired
Inherited hemophilia A, which is due to defective FVIII gene causing 
defi ciency of FVIII leads to a lifelong bleeding tendency needing 
prophylactic FVIII replacement therapy. Women are the obligate 
carriers as daughters of hemophilia A men. An early replacement therapy 
by FVIII, the foreign protein, evokes an inhibitor that is a neutralizing 
IgG4-type alloantibody, which suddenly eliminates the benefi t of the 
FVIII replacement therapy. Usually this complication occurs after the 
twentieth exposure to FVIII, and may associate with danger signals to 
the immune system, typically at any larger bleeding episode.
The typical sites for bleeds in traditional hemophilia are joints and 
less frequently muscles. However, when a sudden bleeding phenotype 
develops multiple large subcutaneous hematomas occur usually 
after a minor challenge, raising suspicion of acquired hemophilia A 
(AHA). In this acute bleeding disorder neutralizing autoantibodies, 
alias inhibitors will ensue against FVIII, upon an immunological 
challenge. This rare immunological complication is aff ecting 1:1.5 
million people, and in young females relates to the postpartum period 
(1:350,000 pregnancies, occurring at day 1 to several months), and in 
patients older than 60 years to cancer or is of unknown etiology (65%) 
[1,2]. Among females, in addition to pregnancy-associated events, 
gynecological and breast and other cancer types may trigger this 
complication. The bleeding phenotype resembles a primary hemostatic 
defect in this acquired disorder, and it is relatively similar to the 
inhibitors, which are encountered among milder forms of hemophilia. 
Main bleeding symptoms include subcutaneous (80%), muscle (45%) 
and gastrointestinal bleeds (25%), and at least 65% of them require 
hemostatic therapy.
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Acquired hemophilia is a rare but severe condition, which is unknown to medical specialties outside hematology. 
Sudden appearance of antibodies against coagulation FVIII is diagnosed by abnormal subcutaneous large and 
multiple hematomas with minor injuries only. APTT is prolonged, FVIII activity variably low and inhibitor titer 
varies, too. The antibodies are typically occurring in women after delivery and later in life at around 60 years 
of life due to immunological challenges, and in association with malignant diseases. Rapid recognition of the 
condition and support of hemostasis together with immunosuppressive therapy is important, since the diagnostic 
delay is a poor prognostic sign. Coagulation experts should be consulted to arrange the management and follow-
up of the patients. Management of bleeds consists of so-called FVIII bypassing agents, activated prothrombin 
complex concentrate, aPCC, recombinant FVIIa or porcine FVIII. The immunotherapy should be continued for 
several weeks according to the timing of the remission. The relapse rate needs to be noted in the future under 
similar situations as the index event occurred. Register data collection is important to characterize this life-
threatening acquired bleeding disorder.
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3. Diagnosis of FVIII inhibitors
The traditional simple screening test of FVIII inhibitors is activated 
partial thromboplastin time, APTT. It is prolonged while PT is normal. 
FVIII levels are low, most often around 2–10 IU/dL. The inhibitor titer 
varies (10–100 BU/mL), in 10% above 100 BU/mL
4. Hemostatic therapy of an inhibitor-positive patient
Treatment targets improvement of hemostasis and eradication 
of the inhibitor. In life-threatening or severe cases plasmapheresis 
or immunoabsorption can foster the hemostatic therapy. The FVIII-
bypassing remedies are needed to establish hemostasis during a 
bleed ing event or prevention of next. They have included activated 
prothrombin complex concentrates (aPCC) and recombinant activated 
FVII (rFVIIa). Also, porcine-derived FVIII is an option.
The novel non-replacement therapies have been developed, 
including emicizumab, a bispecifi c antibody to mimic FVIII to engage 
FIX to the tenase complex. Thus far, its indication is exclusively 
congenital form of hemophilia. In addition to emicizumab, inhibitor 
of tissue factor pathway inhibitor, antiTFPI, concizumab and anti-
thrombin silencing fi tusiran are in the phase II-III programs to enhance 
thrombin generation. These three latter strategies mainly off er long-
term protection against bleeds but are unlikely providing hemostatic 
effi  cacy under a signifi cant bleed or major surgery. These hemostatic 
challenges will need novel approaches during such novel therapies. 
Some minor bleeds or surgeries can be managed with tranexamic acid 
(antifi brinolytic therapy) and a wait and see strategy.
5. Overall management of patients with inhibitors against FVIII
The bypassing therapy with either aPCC or rFVIIa provides the 
early management to stop bleeds as soon as possible. Several doses 
may be needed. The unique strength of porcine FVIII is the allowance 
of laboratory monitoring of FVIII.
The main management target aside reaching hemostasis is to regain 
tolerance to FVIII. That may be achieved in inherited hemophilia in 
60–80% of the cases with immunotolerance therapy induction (ITI) 
with high daily doses of FVIII, usually with the therapeutic agent 
under use while inhibitor appeared or a VWF containing plasma 
concentrate. The novel extended half-life FVIII therapies which are 
coupled to either PEG, albumin, or immunoglobulin Fc-portion may 
off er ITI benefi ts or even reduce frequency of inhibitors, an idea which 
awaits to be proven.
6. Immunosuppressive therapy
Rapid induction of immunosuppressin is critical to control bleeding 
propensity and revert FVIII activity. The immunosuppressive drugs 
include IgG antibody production inhibiting steroids, cyclophos pha-
mide, aza thioprine and rituximab, antiCD20 inhibitor. The treatment 
should last until the inhibitor is below detection (0.6 BU/mL) and 
APTT and FVIII levels are normalized at least for a few weeks. Follow-
up of the patient should be organized for the next 12 months and a 
risk profi le identifi ed, should the inhibitor appear under some future 
immunological challenges.
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Fig. 1. (A) The hemostatic role of platelet surface and FVIII engagement to coagulation. (B) The inhibitor or antibody neutralizing FVIII activity (red arrow) leads to 
reduced FXa activity and thrombin. Thus, less fi brinogen is converted to fi brin which is more susceptible to the fi brinolytic system. This leads to bleeding tendency. 
PP, polyphosphates; PL/PS, phospholipids/phosphatidylserine; TF, tissue factor; SMC, smooth muscle cell.
